Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

HCC in the Setting of Hepatitis B: Asia-Pacific Considerations

Grace LH Wong, MD
Released: June 8, 2021

HCC Risk Reduction: TDF vs ETV for HBV in Chinese Patients in Hong Kong

HCC Risk Reduction: TDF vs ETV for HBV in Chinese Patients in Hong Kong

There are 2 nucleos(t)ide analogues currently recommended for first-line treatment of HBV, tenofovir and ETV. Tenofovir is formulated as tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide, and I will discuss these 2 formulations together as they contain the same active component. These are the drugs commonly used today, but the question remains whether one is better than the other. There have been multiple studies investigating this question in the recent 2-3 years.11

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue